Literature DB >> 9700574

Presence of the 918 mutation in the RET proto-oncogene in a Mexican patient with multiple endocrine neoplasia type 2B.

A Hidalgo1, M E Medrano, S Rodrìguez, C Franco, I Martinez, L Benítez, M Salcedo.   

Abstract

The dominantly inherited Multiple Endocrine Neoplasia cancer syndrome type 2B (MEN2B) is characterized by the presence of medullary thyroid carcinoma (MTC), phaechromocytoma (PHAEO), mucosal neuromas, ganglioneuromas of the intestinal tract, skeletal and ophthalmic abnormalities. MEN2B has been associated with a specific point mutation in the tyrosine kinase domain of the RET proto-oncogene (918RET mutation). We investigated a Mexican patient MEN2B for the presence of the 918RET mutation using the polymerase chain reaction followed by restriction endonuclease digestion. We have detected this mutation in DNA from the patient's MTC, PHAEO, and peripheral blood cells, but not in DNA from the patient's mother, suggesting that this mutation arose de novo. Our results are in agreement with the suggestion that the 918RET mutation is present in a vast majority of MEN2B cases around the world.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9700574

Source DB:  PubMed          Journal:  J Exp Clin Cancer Res        ISSN: 0392-9078


  2 in total

1.  Single oligoarray-based detection of specific M918T mutation in RET oncogene in multiple endocrine neoplasia type 2B.

Authors:  R A Pacheco-Rivera; E Hernández-Zamora; B González-Yebra; K Beattie; R Maldonado-Rodríguez; J C Santiago-Hernández; M E Medrano-Ortiz de Zárate; M Salcedo
Journal:  Clin Exp Med       Date:  2011-01-21       Impact factor: 3.984

2.  Preclinical testing of selective Aurora kinase inhibitors on a medullary thyroid carcinoma-derived cell line.

Authors:  Chiara Tuccilli; Enke Baldini; Natalie Prinzi; Stefania Morrone; Salvatore Sorrenti; Angelo Filippini; Antonio Catania; Stefania Alessandrini; Roberta Rendina; Carmela Coccaro; Massimino D'Armiento; Salvatore Ulisse
Journal:  Endocrine       Date:  2015-07-28       Impact factor: 3.633

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.